Rocket Pharmaceuticals
RCKT
236 hedge funds and large institutions have $722M invested in Rocket Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 112 increasing their positions, 41 reducing their positions, and 35 closing their positions.
173% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 41
172% more call options, than puts
Call options by funds: $3.92M | Put options by funds: $1.44M
37% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 35
5% more funds holding
Funds holding: 225 → 236 (+11)
2% less ownership
Funds ownership: 103.11% → 101.11% (-2%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
48% less capital invested
Capital invested by funds: $1.38B → $722M (-$655M)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$14.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$9.88M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$9.24M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.22M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$5.91M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$25.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.7M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
-$18.4M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$15.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.5M |
RCKT Hedge Fund Activity: Q1 2025 in Review
236 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2025, worth a combined $722M — down 48% from $1.38B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new RCKT positions and 35 closed out — a net gain of 13 holders — while 112 added to existing stakes and 41 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $14.4M. The largest seller was Citadel Advisors, cutting an estimated $25.8M.
- 236 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2025, up from 225 in Q4 2024.
- Funds reported $722M of Rocket Pharmaceuticals stock for Q1 2025, down 48% quarter-over-quarter.
- 48 funds opened new Rocket Pharmaceuticals positions in Q1 2025 and 35 closed out, a net change of +13 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2025 was Morgan Stanley, an estimated $14.4M added.
- The largest Rocket Pharmaceuticals seller in Q1 2025 was Citadel Advisors, an estimated $25.8M sold.
Based on aggregated 13F filings for Q1 2025.